XML 51 R34.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 18, 2023 | Nov. 11, 2022 | Aug. 05, 2013 | Dec. 27, 2023 | Sep. 29, 2021 | Dec. 18, 2020 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Average interest rate, short-term bank deposits in U.S. dollars |  |  |  |  |  |  | 6.20% | 4.84% |
Amortization in R&D expenses |  |  |  |  |  |  | $ 325 | $ 6,019 | $ 1,291
Revenue recognition under milestone method |  | $ 7,500 |  | $ 10,000 | $ 6,000 | $ 2,000 |  |  |
Severance expenses |  |  |  |  |  |  | 432 | $ 468 | $ 383
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned |  |  | $ 10,000 |  |  |  | 10,000 |  |
Research And Development Arrangement Payments Receivable |  |  | $ 250,000 |  |  |  | 200,000 |  |
Accrued milestone payment |  |  |  |  |  |  | 25,500 |  |
License revenue |  |  |  |  |  |  | 23,459 |  |
Deferred revenues included in current liabilities |  |  |  |  |  |  | 11,149 |  |
Deferred revenues included in non current liabilities |  |  |  |  |  |  | $ 25,392 |  |
Options [Member] |  |  |  |  |  |  |  |  |
Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share |  |  |  |  |  |  | 7,921,020 | 8,405,615 | 6,758,300
Master Clinical Agreement One [Member] |  |  |  |  |  |  |  |  |
Investment amount |  |  |  |  |  |  | $ 12,000 |  |
Deferred participation of BMS in R&D expenses |  |  |  |  |  |  | 4,121 |  |
Master Clinical Agreement Two [Member] |  |  |  |  |  |  |  |  |
Investment amount |  |  |  |  |  |  | 20,000 |  |
Deferred participation of BMS in R&D expenses |  |  |  |  |  |  | $ 5,000 |  |
License Agreement With Gilead [Member] |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned | $ 60,000 |  |  |  |  |  |  |  |
Research And Development Arrangement Payments Receivable | $ 788,000 |  |  |  |  |  |  |  |

X
- Definition Amount of accrued milestone payments. + References No definition available. + Details
Name: | cgen_AccruedMilestonePayments
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Deferred participation of BMS in R and D expenses. + References No definition available. + Details
Name: | cgen_DeferredParticipationOfBMSInRAndDExpenses
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenues included in current liabilities. + References No definition available. + Details
Name: | cgen_DeferredRevenuesIncludedInCurrentLiabilities
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenues included in non current liabilities. + References No definition available. + Details
Name: | cgen_DeferredRevenuesIncludedInNonCurrentLiabilities
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of license revenue. + References No definition available. + Details
Name: | cgen_LicenseRevenue
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements. + References No definition available. + Details
Name: | cgen_ResearchAndDevelopmentArrangementPaymentsReceivable
Namespace Prefix: | cgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The weighted average interest rate for short-term bank deposits outside of the domestic currency. + References No definition available. + Details
Name: | cgen_ShortTermBankDepositsWeightedAverageRateForeign
Namespace Prefix: | cgen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_AdjustmentForAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents the aggregate cost of investments accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_SeveranceCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=cgen_LicenseAgreementWithGileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |